The association of protease activated receptor 1 gene -506 I/D polymorphism with disease-free survival in breast cancer patients

Annals of Surgical Oncology

Volumn 19, Issue 4, 2012, Pages 1365-1369

  Eroǧlu, Aydan ^a   Karabiyik, Afife ^a   Akar, Nejat ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 1; PROTHROMBIN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA DETERMINATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDEL MUTATION; LYMPH NODE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENT CANCER;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84862506073     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1969-8     Document Type: Article

References (23)

1. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102:S2-9.
2. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10:355-62. (Pubitemid 44693468)
3. Hirano K, Kanaide H. Role of protease-activated receptor in the vascular system. J Atheroscler Thromb. 2003;10:211-25.
4. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006;32:61-8.
5. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, et al. Proteinase-activated receptors 1 and 4 counter-regulated endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA. 2005;102:216-20. (Pubitemid 40094455)
6. Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res. 2007;5:29-240.
7. Li F, Baykal D, Horaist C, Yan CN, Carr BN, Rao GN, et al. Cloning and identification of regulatory sequences of the human thrombin receptor gene. J Biol Chem. 1996;271:26320-8. (Pubitemid 26347484)
8. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol. 2000;20:585-92. (Pubitemid 30086120)
9. Lurje G, Leers JM, Pohl A, Ozcelik A, Zhang W, Ayazi S, et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg. 2010;251:857-64.
10. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21:78-86.
11. Grisaru-Granovsky S, Tevet A, Bar-Shavit R, Salah Z, Elstein D, Samueloff A, et al. Association study of protease activated receptor 1 gene polymorphisms and adverse pregnancy outcomes: results of a pilot study in Israel. Am J Med Genet A. 2007;143:2557-63. (Pubitemid 350058168)
12. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of factor V 1691G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis. 2007;23:31-4.
13. Cam R, Eroglu A, Egin Y, Akar N. Dihydrofolate reductase (DHFR) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer. Breast Cancer Res Treat. 2009;115:431-2.
14. Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumor biology. Hematol Oncol. 2006;24:126-33. (Pubitemid 44483905)
15. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124:S58-S68.
16. Tormene D, Beltramello P, Perlati M, Brandolin B, Barbar S, De Toffoli G, et al. The risk of cancer progression in women with gynecological malignancies and thrombophilic polymorphisms: a pilot case-control study. Clin Appl Thromb Hemost. 2009;18:535-9.
17. Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, et al. Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res. 2005;25:2561-5. (Pubitemid 41044749)
18. Batistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R, Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol. 2006;12:4179-80. (Pubitemid 44376897)
19. Eroglu A, Ç am R, Eǧin Y, Akar N. Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer. Breast Cancer Res Treat. 2009;116:619-20.
20. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004;2:2107-14. (Pubitemid 40185769)
21. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909-14. (Pubitemid 28364029)
22. Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN. Proteinase-activated receptor-1-triggred activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008;68:1851-61. (Pubitemid 351416571)
23. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, et al. The pattern of protease activated receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol. 2006;103:802-6. (Pubitemid 44821301)